KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Return on Equity (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Return on Equity for 15 consecutive years, with 10.31% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 879.0% to 10.31% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10.31% through Dec 2025, down 879.0% year-over-year, with the annual reading at 1.82% for FY2025, 66.0% down from the prior year.
  • Return on Equity hit 10.31% in Q4 2025 for Inovio Pharmaceuticals, down from 8.35% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.25% in Q2 2021 to a low of 10.31% in Q4 2025.
  • Historically, Return on Equity has averaged 1.91% across 5 years, with a median of 1.14% in 2023.
  • Biggest five-year swings in Return on Equity: surged 94bps in 2021 and later plummeted -879bps in 2025.
  • Year by year, Return on Equity stood at 0.71% in 2021, then tumbled by -60bps to 1.14% in 2022, then grew by 7bps to 1.06% in 2023, then tumbled by -44bps to 1.52% in 2024, then plummeted by -579bps to 10.31% in 2025.
  • Business Quant data shows Return on Equity for INO at 10.31% in Q4 2025, 8.35% in Q3 2025, and 2.32% in Q2 2025.